Indeed, a significant proportion of ESR1 LBD point mutations were identified in metastatic tumors that were extensively treated with AIs, suggesting that such mutations may be enriched in breast tumors upon AI treatment[53]. Here, ESR1 is linked to metastatic neoplasm.